Trial Profile
A multicenter, retrospective cohort study evaluating efficacy, retention, and tolerability of add-on brivaracetam (BRV) in the treatment of epilepsies in clinical practice
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 12 Oct 2021
Price :
$35
*
At a glance
- Drugs Brivaracetam (Primary)
- Indications Epilepsy; Generalised epilepsy; Partial epilepsies
- Focus Adverse reactions; Therapeutic Use
- 04 Oct 2021 Results published in the Epilepsia
- 12 Jan 2018 New trial record